- Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
- NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
- New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
- NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
- Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
- NeuroStar TMS Patient Access Expands Through Lucet Health Policy Update
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
- NeuroStar TMS Receives Expanded Regulatory Approval in Japan
- NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
More ▼
Key statistics
On Tuesday, Neuronetics Inc (STIM:NMQ) closed at 2.08, 101.94% above the 52 week low of 1.03 set on Oct 30, 2023.
52-week range
Open | 2.26 |
---|---|
High | 2.35 |
Low | 2.05 |
Bid | 0.8361 |
Offer | 3.32 |
Previous close | 2.08 |
Average volume | 138.96k |
---|---|
Shares outstanding | 30.00m |
Free float | 28.10m |
P/E (TTM) | -- |
Market cap | 62.39m USD |
EPS (TTM) | -0.9484 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼